Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Inventory (2017 - 2023)

Avalo Therapeutics filings provide 7 years of Inventory readings, the most recent being $18000.0 for Q2 2023.

  • On a quarterly basis, Inventory fell 21.74% to $18000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $18000.0, a 21.74% decrease, with the full-year FY2022 number at $20000.0, down 47.37% from a year prior.
  • Inventory hit $18000.0 in Q2 2023 for Avalo Therapeutics, down from $19000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $1.0 million in Q1 2019 to a low of $3000.0 in Q4 2020.
  • Median Inventory over the past 5 years was $20000.0 (2021), compared with a mean of $107007.2.
  • Biggest five-year swings in Inventory: tumbled 98.45% in 2020 and later soared 1166.67% in 2021.
  • Avalo Therapeutics' Inventory stood at $21334.0 in 2019, then tumbled by 85.94% to $3000.0 in 2020, then soared by 1166.67% to $38000.0 in 2021, then crashed by 47.37% to $20000.0 in 2022, then dropped by 10.0% to $18000.0 in 2023.
  • The last three reported values for Inventory were $18000.0 (Q2 2023), $19000.0 (Q1 2023), and $20000.0 (Q4 2022) per Business Quant data.